Several studies presented at ADA 2016 discussed going beyond basal insulin treatments for patients with type 2 diabetes.
Several studies presented at the 2016 American Diabetes Association annual meeting dealt with going beyond basal insulin treatments for type 2 diabetes mellitus (DM) patients. Here are the highlights from four abstracts on treatment intensification options.
Insulin Degludec/Liraglutide vs. Insulin Glargine. Abstract link.
Patients with T2DM treated with insulin degludec/liraglutide have a greater chance of reaching glycemic targets.
Faster-acting Insulin Aspart. Abstract link.
Faster-acting Insulin vs. Basal Insulin. Abstract link.
Faster aspart in a basal-bonus regimen provided superior glycemic control versus basal insulin only.
Insulin Glargine/Lixisenatide vs. Insulin Glargine. Abstract link.
A fixed-ratio combination of insulin glargine/lixisenatide is more effective and safer than insulin glargine in patients with T2DM.